Nanomedicine applies nanoscale materials and devices to diagnose, treat, and prevent disease with greater precision than conventional methods. A key focus is targeted drug delivery, where nanoparticles are engineered to carry therapeutic molecules directly to diseased cells while sparing healthy tissue. For cancers, nanocarriers can exploit abnormal tumor blood vessels and specific surface markers to accumulate drugs in tumors, increasing local concentration and reducing systemic toxicity.

Different types of nanoparticles are used, including liposomes, polymeric nanoparticles, dendrimers, inorganic particles such as gold or silica, and lipid based nanocarriers. Their size, surface charge, and coatings are tuned to improve stability in the bloodstream, evade immune clearance, and recognize specific cell types. Some are stimuli responsive, releasing drugs in response to pH, temperature, enzymes, or external triggers such as light or magnetic fields.

Nanomedicine also advances imaging and diagnostics. Contrast agents at the nanoscale can enhance MRI, CT, and optical imaging, allowing earlier detection and better monitoring of disease progression and treatment response. Theranostic systems combine therapy and diagnosis in a single platform, enabling real time tracking of where the drug goes and how well it works.

Despite promising results in preclinical models and a number of approved nanoformulations, challenges remain. These include large scale manufacturing with consistent quality, long term safety and biodistribution, potential toxicity of some nanomaterials, and regulatory complexity. Researchers are working on more biocompatible and biodegradable designs, improved targeting strategies, and personalized nanomedicine approaches that match specific nanoparticle systems to individual patients and diseases.